Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...
At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint ...
Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...
The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...
The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...
Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...
Asian News International on MSN3d
Dr Prem's Medical Tourism & Wellness Masterclass, FAM Trip & B2B Meetings: A Sold-Out Global Success in Knowledge Sharing & NetworkingRising Influence in Global Medical & Wellness Tourism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback